Detailed revisions to the subordinate regulation following the amendment of the Act on the Safety of Regenerative Medicine in Japan
{{output}}
The amended Act on the Safety of Regenerative Medicine (RM Act) in Japan expands its scope to include in vivo gene therapy and related technologies, classifying them into Class I, the highest-risk category. Furthermore, the amended RM Act introduces additional... ...
